These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24306326)

  • 1. Critical evaluation of human oral bioavailability for pharmaceutical drugs by using various cheminformatics approaches.
    Kim MT; Sedykh A; Chakravarti SK; Saiakhov RD; Zhu H
    Pharm Res; 2014 Apr; 31(4):1002-14. PubMed ID: 24306326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing Enhanced Blood-Brain Barrier Permeability Models: Integrating External Bio-Assay Data in QSAR Modeling.
    Wang W; Kim MT; Sedykh A; Zhu H
    Pharm Res; 2015 Sep; 32(9):3055-65. PubMed ID: 25862462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Predictions of Oral Bioavailability of Candidate Drugs in Man with New Machine Learning Methodology.
    Fagerholm U; Hellberg S; Spjuth O
    Molecules; 2021 Apr; 26(9):. PubMed ID: 33925103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions.
    Sedykh A; Fourches D; Duan J; Hucke O; Garneau M; Zhu H; Bonneau P; Tropsha A
    Pharm Res; 2013 Apr; 30(4):996-1007. PubMed ID: 23269503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship.
    Andrews CW; Bennett L; Yu LX
    Pharm Res; 2000 Jun; 17(6):639-44. PubMed ID: 10955834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting chemical ocular toxicity using a combinatorial QSAR approach.
    Solimeo R; Zhang J; Kim M; Sedykh A; Zhu H
    Chem Res Toxicol; 2012 Dec; 25(12):2763-9. PubMed ID: 23148656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
    Martin E; Mukherjee P; Sullivan D; Jansen J
    J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches.
    Low Y; Uehara T; Minowa Y; Yamada H; Ohno Y; Urushidani T; Sedykh A; Muratov E; Kuz'min V; Fourches D; Zhu H; Rusyn I; Tropsha A
    Chem Res Toxicol; 2011 Aug; 24(8):1251-62. PubMed ID: 21699217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QSAR model for drug human oral bioavailability.
    Yoshida F; Topliss JG
    J Med Chem; 2000 Jun; 43(13):2575-85. PubMed ID: 10891117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates.
    Shen M; Xiao Y; Golbraikh A; Gombar VK; Tropsha A
    J Med Chem; 2003 Jul; 46(14):3013-20. PubMed ID: 12825940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing Oral Bioavailability in Drug Discovery: An Overview of Design and Testing Strategies and Formulation Options.
    Aungst BJ
    J Pharm Sci; 2017 Apr; 106(4):921-929. PubMed ID: 27986598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Informing the Human Plasma Protein Binding of Environmental Chemicals by Machine Learning in the Pharmaceutical Space: Applicability Domain and Limits of Predictability.
    Ingle BL; Veber BC; Nichols JW; Tornero-Velez R
    J Chem Inf Model; 2016 Nov; 56(11):2243-2252. PubMed ID: 27684444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico Prediction of Compounds Binding to Human Plasma Proteins by QSAR Models.
    Sun L; Yang H; Li J; Wang T; Li W; Liu G; Tang Y
    ChemMedChem; 2018 Mar; 13(6):572-581. PubMed ID: 29057587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive QSAR modeling workflow, model applicability domains, and virtual screening.
    Tropsha A; Golbraikh A
    Curr Pharm Des; 2007; 13(34):3494-504. PubMed ID: 18220786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models.
    Contrera JF; Kruhlak NL; Matthews EJ; Benz RD
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):172-82. PubMed ID: 17703860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of pseudo-equilibrium constant affords improved QSAR models of human plasma protein binding.
    Zhu XW; Sedykh A; Zhu H; Liu SS; Tropsha A
    Pharm Res; 2013 Jul; 30(7):1790-8. PubMed ID: 23568522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
    Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critically Assessing the Predictive Power of QSAR Models for Human Liver Microsomal Stability.
    Liu R; Schyman P; Wallqvist A
    J Chem Inf Model; 2015 Aug; 55(8):1566-75. PubMed ID: 26170251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability prediction based on molecular structure for a diverse series of drugs.
    Turner JV; Maddalena DJ; Agatonovic-Kustrin S
    Pharm Res; 2004 Jan; 21(1):68-82. PubMed ID: 14984260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.